What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes

Journal of Cardiovascular Translational Research

Volumn 5, Issue 4, 2012, Pages 463-478

  Pop Busui, Rodica ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular autonomic dysfunction; Diabetes mellitus; Neuropathy

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; C PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; METFORMIN; METOPROLOL; NEBIVOLOL; PLACEBO; THIOCTIC ACID; VERAPAMIL;

ARTICLE; AUTONOMIC NEUROPATHY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE DURATION; DISEASE SEVERITY; EXERCISE TOLERANCE; FOLLOW UP; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC SYNDROME X; MORTALITY; MYOCARDIAL DISEASE; MYOCARDIAL DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRESSORECEPTOR REFLEX; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; SYMPATHETIC NERVE; TACHYCARDIA; TILT TABLE TEST;

AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NERVOUS SYSTEM DISEASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIABETIC NEUROPATHIES; HEMODYNAMICS; HUMANS; PREDICTIVE VALUE OF TESTS; PREVENTIVE HEALTH SERVICES; PROGNOSIS; REFLEX, ABNORMAL; RISK ASSESSMENT; RISK FACTORS;

EID: 84866076600     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9367-6     Document Type: Article

References (125)

1. DCCT. (1998). The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia, 41, 416-423.
2. Pop-Busui, R. (2010). Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care, 33, 434-441.
3. Pop-Busui, R., Low, P. A.,Waberski, B. H., Martin, C. L., Albers, J. W., Feldman, E. L., Sommer, C., Cleary, P. A., Lachin, J. M., & Herman, W. H. (2009). Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/ EDIC). Circulation, 119, 2886-2893.
4. Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop-Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., et al. (2012). Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metabolism Research and Reviews (in press).
5. Kempler, P., Tesfaye, S., Chaturvedi, N., Stevens, L. K., Webb, D. J., Eaton, S., Kerenyi, Z., Tamas, G., Ward, J. D., & Fuller, J. H. (2002). Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabetic Medicine, 19, 900-909.
6. Low, P. A., Benrud-Larson, L. M., Sletten, D. M., Opfer- Gehrking, T. L., Weigand, S. D., O'Brien, P. C., Suarez, G. A., & Dyck, P. J. (2004). Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care, 27, 2942-2947.
7. Kennedy, W. R., Navarro, X., & Sutherland, D. E. (1995). Neuropathy profile of diabetic patients in a pancreas transplantation program. Neurology, 45, 773-780.
8. Singh, J. P., Larson, M. G., O'Donnell, C. J., Wilson, P. F., Tsuji, H., Lloyd-Jones, D. M., & Levy, D. (2000). Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). The American Journal of Cardiology, 86, 309-312.
9. Wu, J. S., Yang, Y. C., Lin, T. S., Huang, Y. H., Chen, J. J., Lu, F. H., Wu, C. H., & Chang, C. J. (2007). Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. Journal of Clinical Endocrinology and Metabolism, 92, 3885-3889.
10. Navarro, X., Kennedy, W. R., & Sutherland, D. E. (1991). Autonomic neuropathy and survival in diabetes mellitus: effects of pancreas transplantation. Diabetologia, 34(Suppl 1), S108-S112.
11. O'Brien, I. A., McFadden, J. P., & Corrall, R. J. (1991). The influence of autonomic neuropathy on mortality in insulindependent diabetes. Quarterly Journal of Medicine, 79, 495-502.
12. Ewing, D. J., Campbell, I. W., & Clarke, B. F. (1980). Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Annals of Internal Medicine, 92, 308-311.
13. Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003). The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care, 26, 1895-1901.
14. Soedamah-Muthu, S. S., Chaturvedi, N., Witte, D. R., Stevens, L. K., Porta, M., & Fuller, J. H. (2008). Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care, 31, 1360-1366.
15. Gerritsen, J., Dekker, J. M., TenVoorde, B. J., Kostense, P. J., Heine, R. J., Bouter, L. M., Heethaar, R. M., & Stehouwer, C. D. (2001). Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care, 24, 1793-1798.
16. Lykke, J. A., Tarnow, L., Parving, H. H., & Hilsted, J. (2008). A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scandinavian Journal of Clinical and Laboratory Investigation, 68, 654-659.
17. Ziegler, D., Zentai, C. P., Perz, S., Rathmann, W., Haastert, B., Doring, A., & Meisinger, C. (2008). Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care, 31, 556-561.
18. Pop-Busui, R., Evans, G. W., Gerstein, H. C., Fonseca, V., Fleg, J. L., Hoogwerf, B. J., Genuth, S., Grimm, R. H., Corson, M. A., & Prineas, R. (2010). Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care, 33, 1578-1584.
19. Nordin, C. (2010). The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia, 53, 1552-1561.
20. Landstedt-Hallin, L., Englund, A., Adamson, U., & Lins, P. E. (1999). Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. Journal of Internal Medicine, 246, 299-307.
21. Robinson, R. T., Harris, N. D., Ireland, R. H., Macdonald, I. A., & Heller, S. R. (2004). Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with type 1 diabetes. Diabetologia, 47, 312-315.
22. DCCT. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. The New England Journal of Medicine, 329, 977-986.
23. UKPDS. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 837-853.
24. Cryer, P. E. (2001). Hypoglycemia-associated autonomic failure in diabetes. American Journal of Physiology, Endocrinology and Metabolism, 281, E1115-E1121.
25. Adler, G. K., Bonyhay, I., Failing, H., Waring, E., Dotson, S., & Freeman, R. (2009). Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes, 58, 360-366.
26. Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003). Diabetic autonomic neuropathy. Diabetes Care, 26, 1553-1579.
27. Young, L. H., Wackers, F. J., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009). Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. Journal of the American Medical Association, 301, 1547-1555.
28. Hage, F. G., & Iskandrian, A. E. (2011). Cardiovascular imaging in diabetes mellitus. Journal of Nuclear Cardiology, 18, 959-965.
29. Vinik, A. I., & Ziegler, D. (2007). Diabetic cardiovascular autonomic neuropathy. Circulation, 115, 387-397.
30. Axelrod, S., Lishner, M., Oz, O., Bernheim, J., & Ravid, M. (1987). Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic nervous control in chronic renal failure. Nephron, 45, 202-206.
31. Givertz, M. M., Sawyer, D. B., & Colucci, W. S. (2001). Antioxidants and myocardial contractility: illuminating the "Dark Side" of beta-adrenergic receptor activation? Circulation, 103, 782-783.
32. Iwai-Kanai, E., Hasegawa, K., Araki, M., Kakita, T., Morimoto, T., & Sasayama, S. (1999). Alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation, 100, 305-311.
33. Paulson, D. J., & Light, K. E. (1981). Elevation of serum and ventricular norepinephrine content in the diabetic rat. Research Communications in Chemical Pathology and Pharmacology, 33, 559-562.
34. Drake-Holland, A. J., Van der Vusse, G. J., Roemen, T. H., Hynd, J. W., Mansaray, M., Wright, Z. M., & Noble, M. I. (2001). Chronic catecholamine depletion switches myocardium from carbohydrate to lipid utilisation. Cardiovascular Drugs and Therapy, 15, 111-117.
35. Schrauwen, P., Hoeks, J., & Hesselink, M. K. (2006). Putative function and physiological relevance of the mitochondrial uncoupling protein-3: involvement in fatty acid metabolism? Progress in Lipid Research, 45, 17-41.
36. Pop-Busui, R., Kirkwood, I., Schmid, H., Marinescu, V., Schroeder, J., Larkin, D., Yamada, E., Raffel, D. M., & Stevens, M. J. (2004). Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. Journal of the American College of Cardiology, 44, 2368-2374.
37. An, D., & Rodrigues, B. (2006). Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. American Journal of Physiology-Heart and Circulatory Physiology, 291, H1489-H1506.
38. Goodwin, G. W., Ahmad, F., Doenst, T., & Taegtmeyer, H. (1998). Energy provision from glycogen, glucose, and fatty acids on adrenergic stimulation of isolated working rat hearts. American Journal of Physiology, 274, H1239-H1247.
39. Brown, M., Marshall, D. R., Sobel, B. E., & Bergmann, S. R. (1987). Delineation of myocardial oxygen utilization with carbon-11-labeled acetate. Circulation, 76, 687-696.
40. Collins-Nakai, R. L., Noseworthy, D., & Lopaschuk, G. D. (1994). Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. American Journal of Physiology, 267, H1862-H1871.
41. Herrero, P., Peterson, L. R., McGill, J. B., Matthew, S., Lesniak, D., Dence, C., & Gropler, R. J. (2006). Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. Journal of the American College of Cardiology, 47, 598-604.
42. Feuvray, D., & Lopaschuk, G. D. (1997). Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovascular Research, 34, 113-120.
43. Hirabara, S. M., Silveira, L. R., Alberici, L. C., Leandro, C. V., Lambertucci, R. H., Polimeno, G. C., Cury Boaventura, M. F., Procopio, J., Vercesi, A. E., & Curi, R. (2006). Acute effect of fatty acids on metabolism and mitochondrial coupling in skeletal muscle. Biochimica et Biophysica Acta, 1757, 57-66.
44. Chatham, J. C., & McNeill, J. H. (Eds.). (1996). The heart in diabetes. Norwell, MA: Kluwer Academic Publishers.
45. Francis, G. S. (2001). Diabetic cardiomyopathy: fact or fiction? Heart, 85, 247-248.
46. Frustaci, A., Kajstura, J., Chimenti, C., Jakoniuk, I., Leri, A., Maseri, A., Nadal-Ginard, B., & Anversa, P. (2000). Myocardial cell death in human diabetes. Circulation Research, 87, 1123-1132.
47. Packer, M., O'Connor, C. M., Ghali, J. K., Pressler, M. L., Carson, P. E., Belkin, R. N., Miller, A. B., Neuberg, G. W., Frid, D., Wertheimer, J. H., et al. (1996). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. The New England Journal of Medicine, 335, 1107-1114.
48. Buxton, D. B., Schwaiger, M., Nguyen, A., Phelps, M. E., & Schelbert, H. R. (1988). Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circulation Research, 63, 628-634.
49. Eichhorn, E. J., & Bristow, M. R. (1996). Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation, 94, 2285-2296.
50. Katz, A. M. (1986). Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation, 73, III184-III190.
51. Mueller, H. S., & Ayres, S. M. (1977). The role of propranolol in the treatment of acute myocardial infarction. Progress in Cardiovascular Diseases, 19, 405-412.
52. Fang, Z. Y., Najos-Valencia, O., Leano, R., & Marwick, T. H. (2003). Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine. Journal of the American College of Cardiology, 42, 446-453.
53. Vered, A., Battler, A., Segal, P., Liberman, D., Yerushalmi, Y., Berezin, M., & Neufeld, H. N. (1984). Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). The American Journal of Cardiology, 54, 633-637.
54. Sacre, J. W., Franjic, B., Jellis, C. L., Jenkins, C., Coombes, J. S., & Marwick, T. H. (2010). Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC. Cardiovascular Imaging, 3, 1207-1215.
55. Fang, Z. Y., Prins, J. B., & Marwick, T. H. (2004). Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocrine Reviews, 25, 543-567.
56. Fang, Z. Y., Yuda, S., Anderson, V., Short, L., Case, C., & Marwick, T. H. (2003). Echocardiographic detection of early diabetic myocardial disease. Journal of the American College of Cardiology, 41, 611-617.
57. Rosengard-Barlund, M., Bernardi, L., Fagerudd, J., Mantysaari, M., Af Bjorkesten, C. G., Lindholm, H., Forsblom, C., Waden, J., & Groop, P. H. (2009). Early autonomic dysfunction in type 1 diabetes: a reversible disorder? Diabetologia, 52, 1164-1172.
58. La Rovere, M. T., Bigger, J. T., Jr., Marcus, F. I., Mortara, A., & Schwartz, P. J. (1998). Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet, 351, 478-484.
59. La Rovere, M. T., Pinna, G. D., Maestri, R., Robbi, E., Caporotondi, A., Guazzotti, G., Sleight, P., & Febo, O. (2009). Prognostic implications of baroreflex sensitivity in heart failure patients in the betablocking era. Journal of the American College of Cardiology, 53, 193-199.
60. Ormezzano, O., Quesada, J. L., Pierre, H., Mallion, J. M., & Baguet, J. P. (2008). Evaluation of the prognostic value of baroreflex sensitivity in hypertensive patients: the EVABAR study. Journal of Hypertension, 26, 1373-1378.
61. Gerson, M. C., Caldwell, J. H., Ananthasubramaniam, K., Clements, I. P., Henzlova, M. J., Amanullah, A., & Jacobson, A. F. (2011). Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circulation. Cardiovascular Imaging, 4, 87-93.
62. Swanson, S., Mueller, G., Raffel, D., Duvernoy, C. S., Plunkett, C., Stevens, M., & Pop-Busui, R. (2011). Left ventricle function and sympathetic innervation in type 1 diabetes. Circulation, 124, A15606.
63. Panzer, C., Lauer, M. S., Brieke, A., Blackstone, E., & Hoogwerf, B. (2002). Association of fasting plasma glucose with heart rate recovery in healthy adults: a population-based study. Diabetes, 51, 803-807.
64. Ziegler, D., Zentai, C., Perz, S., Rathmann, W., Haastert, B., Meisinger, C., & Lowel, H. (2006). Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Experimental and Clinical Endocrinology & Diabetes, 114, 153-159.
65. Vinik, A. I., Maser, R. E., & Ziegler, D. (2011). Autonomic imbalance: prophet of doom or scope for hope? Diabetic Medicine, 28, 643-651.
66. Carnethon, M. R., Prineas, R. J., Temprosa, M., Zhang, Z. M., Uwaifo, G., & Molitch, M. E. (2006). The association among autonomic nervous system function, incident diabetes, and intervention arm in the diabetes prevention program. Diabetes Care, 29, 914-919.
67. Chang, C. J., Yang, Y. C., Lu, F. H., Lin, T. S., Chen, J. J., Yeh, T. L., Wu, C. H., & Wu, J. S. (2010). Altered cardiac autonomic function may precede insulin resistance in metabolic syndrome. American Journal of Medicine, 123, 432-438.
68. Laitinen, T., Lindstrom, J., Eriksson, J., Ilanne-Parikka, P., Aunola, S., Keinanen-Kiukaanniemi, S., Tuomilehto, J., & Uusitupa, M. (2011). Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance. Diabetic Medicine, 28, 699-704.
69. Converse, R. L., Jr., Jacobsen, T. N., Toto, R. D., Jost, C. M., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992). Sympathetic overactivity in patients with chronic renal failure. The New England Journal of Medicine, 327, 1912-1918.
70. Siddiqi, L., Joles, J. A., Grassi, G., & Blankestijn, P. J. (2009). Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? Journal of Hypertension, 27, 1341-1349.
71. Brotman, D. J., Bash, L. D., Qayyum, R., Crews, D., Whitsel, E. A., Astor, B. C., & Coresh, J. (2010). Heart rate variability predicts ESRD and CKD-related hospitalization. Journal of the American Society of Nephrology, 21, 1560-1570.
72. Spallone, V., Gambardella, S., Maiello, M. R., Barini, A., Frontoni, S., & Menzinger, G. (1994). Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care, 17, 578-584.
73. Locatelli, F., Marcelli, D., & Conte, F. (1997). Dialysis patient outcomes in Europe vs the USA. Why do Europeans live longer? Nephrology, Dialysis, Transplantation, 12, 1816-1819.
74. Locatelli, F., Marcelli, D., Conte, F., D'Amico, M., Del Vecchio, L., Limido, A., Malberti, F., & Spotti, D. (2001). Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. Journal of the American Society of Nephrology, 12, 2411-2417.
75. Manjunath, G., Levey, A. S., & Sarnak, M. J. (2002). How can the cardiac death rate be reduced in dialysis patients? Seminars in Dialysis, 15, 18-20.
76. Hathaway, D. K., Cashion, A. K., Milstead, E. J., Winsett, R. P., Cowan, P. A., Wicks, M. N., & Gaber, A. O. (1998). Autonomic dysregulation in patients awaiting kidney transplantation. American Journal of Kidney Diseases, 32, 221-229.
77. Ranpuria, R., Hall, M., Chan, C. T., & Unruh, M. (2008). Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV. Nephrology, Dialysis, Transplantation, 23, 444-449.
78. Campese, V. M., Romoff, M. S., Levitan, D., Lane, K., & Massry, S. G. (1981). Mechanisms of autonomic nervous system dysfunction in uremia. Kidney International, 20, 246-253.
79. Brown, D. W., Giles, W. H., & Croft, J. B. (2000). Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. American Heart Journal, 140, 848-856.
80. Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel, W. B., & Castelli, W. P. (1987). Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. The American Journal of Cardiology, 60, 560-565.
81. Nishimura, M., Hashimoto, T., Kobayashi, H., Fukuda, T., Okino, K., Yamamoto, N., Nakamura, N., Yoshikawa, T., Takahashi, H., & Ono, T. (2004). Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in diabetic haemodialysis patients. Nephrology, Dialysis, Transplantation, 19, 2532-2538.
82. Pacher, P., Liaudet, L., Soriano, F. G., Mabley, J. G., Szabo, E., & Szabo, C. (2002). The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes, 51, 514-521.
83. Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008). Diabetic neuropathy: mechanisms to management. Pharmacology and Therapeutics, 120, 1-34.
84. Witzke, K. A., Vinik, A. I., Grant, L. M., Grant, W. P., Parson, H. K., Pittenger, G. L., & Burcus, N. (2011). Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diabetes Care, 34, 1617-1621.
85. Wang, Y., Schmeichel, A. M., Iida, H., Schmelzer, J. D., & Low, P. A. (2006). Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. Journal of Neurological Sciences, 247, 47-52.
86. Cameron, N. E., & Cotter, M. A. (2008). Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Current Drug Targets, 9, 60-67.
87. Kellogg, A. P., Wiggin, T., Larkin, D., Hayes, J., Stevens, M., & Pop-Busui, R. (2007). Protective effects of cyclooxygenase-2 gene inactivation against peripheral nerve dysfunction and intraepidermal nerve fibers loss in experimental diabetes. Diabetes, 56, 2997-3005.
88. Lieb, D. C., Parson, H. K., Mamikunian, G., & Vinik, A. I. (2012). Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Experimental Diabetes Research, 2012, 878760.
89. Duchen, L. W., Anjorin, A., Watkins, P. J., & Mackay, J. D. (1980). Pathology of autonomic neuropathy in diabetes mellitus. Annals of Internal Medicine, 92, 301-303.
90. Purewal, T. S., Goss, D. E., Zanone, M. M., Edmonds, M. E., & Watkins, P. J. (1995). The splanchnic circulation and postural hypotension in diabetic autonomic neuropathy. Diabetic Medicine, 12, 513-522.
91. Ejskjaer, N., Arif, S., Dodds, W., Zanone, M. M., Vergani, D., Watkins, P. J., & Peakman, M. (1999). Prevalence of autoantibodies to autonomic nervous tissue structures in type 1 diabetes mellitus. Diabetic Medicine, 16, 544-549.
92. Rabinowe, S. L., Brown, F. M., Watts, M., & Smith, A. M. (1990). Complement-fixing antibodies to sympathetic and parasympathetic tissues in IDDM. Autonomic brake index and heartrate variation. Diabetes Care, 13, 1084-1088.
93. Stroud, C. R., Heller, S. R., Ward, J. D., Hardisty, C. A., & Weetman, A. P. (1997). Analysis of antibodies against components of the autonomic nervous system in diabetes mellitus. QJM, 90, 577-585.
94. Granberg, V., Ejskjaer, N., Peakman, M., & Sundkvist, G. (2005). Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care, 28, 1959-1964.
95. Stella, P., Ellis, D., Maser, R. E., & Orchard, T. J. (2000). Cardiovascular autonomic neuropathy (expiration and inspiration ratio) in type 1 diabetes. Incidence and predictors. Journal of Diabetes and its Complications, 14, 1-6.
96. Witte, D. R., Tesfaye, S., Chaturvedi, N., Eaton, S. E., Kempler, P., & Fuller, J. H. (2005). Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia, 48, 164-171.
97. Taskiran, M., Rasmussen, V., Rasmussen, B., Fritz-Hansen, T., Larsson, H. B., Jensen, G. B., & Hilsted, J. (2004). Left ventricular dysfunction in normotensive type 1 diabetic patients: the impact of autonomic neuropathy. Diabetic Medicine, 21, 524-530.
98. Pfeifer, M. A., Weinberg, C. R., Cook, D. L., Reenan, A., Halter, J. B., Ensinck, J. W., & Porte, D., Jr. (1984). Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care, 7, 447-453.
99. Nauman, J., Janszky, I., Vatten, L. J., & Wisloff, U. (2011). Temporal changes in resting heart rate and deaths from ischemic heart disease. Journal of the American Medical Association, 306, 2579-2587.
100. Furlan, R., Guzzetti, S., Crivellaro, W., Dassi, S., Tinelli, M., Baselli, G., Cerutti, S., Lombardi, F., Pagani, M., & Malliani, A. (1990). Continuous 24-hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation, 81, 537-547.
101. Spallone, V., Bernardi, L., Ricordi, L., Solda, P., Maiello, M. R., Calciati, A., Gambardella, S., Fratino, P., & Menzinger, G. (1993). Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes, 42, 1745-1752.
102. Lurbe, E., Redon, J., Kesani, A., Pascual, J. M., Tacons, J., Alvarez, V., & Batlle, D. (2002). Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. The New England Journal of Medicine, 347, 797-805.
103. Schwartz, P. J., La Rovere, M. T., & Vanoli, E. (1992). Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation, 85, I77-I91.
104. Schwartz, P. J., La Rovere, M. T., & Vanoli, E. (1996). Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology, 46, 1470.
105. Schwartz, P. J., La Rovere, M. T., & Vanoli, E. (1996). Assessment: Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 46, 873-880.
106. Low, P. A., Denq, J. C., Opfer-Gehrking, T. L., Dyck, P. J., O'Brien, P. C., & Slezak, J. M. (1997). Effect of age and gender on sudomotor and cardiovagal function and blood pressure response to tilt in normal subjects. Muscle & Nerve, 20, 1561-1568.
107. Boulton, A. J., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., Malik, R. A., Maser, R. E., Sosenko, J. M., & Ziegler, D. (2005). Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care, 28, 956-962.
108. England, J. D., Gronseth, G. S., Franklin, G., Carter, G. T., Kinsella, L. J., Cohen, J. A., Asbury, A. K., Szigeti, K., Lupski, J. R., Latov, N., et al. (2009). Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle & Nerve, 39, 106-115.
109. Bernardi, L., Spallone, V., Stevens, M., Hilsted, J., Frontoni, S., Pop-Busui, R., Ziegler, D., Kempler, P., Freeman, R., Low, P., et al. (2012). Investigation methods for cardiac autonomic function in human research studies. Diabetes Metabolism Research and Reviews (in press).
110. Bernardi, L., Spallone, V., Stevens, M., Hilsted, J., Frontoni, S., Pop-Busui, R., Ziegler, D., Kempler, P., Freeman, R., Low, P., et al. (1996). Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation, 93, 1043-1065.
111. Pichot, V., Gaspoz, J. M., Molliex, S., Antoniadis, A., Busso, T., Roche, F., Costes, F., Quintin, L., Lacour, J. R., & Barthelemy, J. C. (1999). Wavelet transform to quantify heart rate variability and to assess its instantaneous changes. Journal of Applied Physiology, 86, 1081-1091.
112. Toledo, E., Gurevitz, O., Hod, H., Eldar, M., & Akselrod, S. (2003). Wavelet analysis of instantaneous heart rate: a study of autonomic control during thrombolysis. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 284, R1079-R1091.
113. Raffel, D. M., & Wieland, D. M. (2001). Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nuclear Medicine and Biology, 28, 541-559.
114. Stevens, M. J., Raffel, D. M., Allman, K. C., Dayanikli, F., Ficaro, E., Sandford, T., Wieland, D. M., Pfeifer, M. A., & Schwaiger, M. (1998). Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation, 98, 961-968.
115. Stevens, M. J., Raffel, D. M., Allman, K. C., Schwaiger, M., & Wieland, D. M. (1999). Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism, 48, 92-101.
116. Schnell, O.,Muhr, D.,Weiss,M., Dresel, S., Haslbeck,M.,&Standl, E. (1996). Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes, 45, 801-805.
117. Caldwell, J. H., Link, J. M., Levy, W. C., Poole, J. E., & Stratton, J. R. (2008). Evidence for pre- to postsynaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure. Journal of Nuclear Medicine, 49, 234-241.
118. Hamner, J. W., & Taylor, J. A. (2001). Automated quantification of sympathetic beat-by-beat activity, independent of signal quality. Journal of Applied Physiology, 91, 1199-1206.
119. DCCT/EDIC, Writing, and Group. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. Journal of the American Medical Association, 290, 2159-2167.
120. Azad, N., Emanuele, N. V., Abraira, C., Henderson, W. G., Colwell, J., Levin, S. R., Nuttall, F. Q., Comstock, J. P., Sawin, C. T., Silbert, C., et al. (1999). The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). Journal of Diabetes and its Complications, 13, 307-313.
121. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine, 360, 129-139.
122. Gaede, P., Vedel, P., Larsen, N., Jensen, G. V., Parving, H. H., & Pedersen, O. (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal of Medicine, 348, 383-393.
123. Carnethon, M. R., Jacobs, D. R., Jr., Sidney, S., & Liu, K. (2003). Influence of autonomic nervous system dysfunction on the development of type 2 diabetes: the CARDIA study. Diabetes Care, 26, 3035-3041.
124. Carnethon, M. R., Jacobs, D. R., Jr., Sidney, S., Sternfeld, B., Gidding, S. S., Shoushtari, C., & Liu, K. (2005). A longitudinal study of physical activity and heart rate recovery: CARDIA, 1987-1993. Medicine and Science in Sports and Exercise, 37, 606-612.
125. Maser, R. E., & Lenhard, M. J. (2007). An overview of the effect of weight loss on cardiovascular autonomic function. Current Diabetes Reviews, 3, 204-211.